Viking Therapeutics (VKTX) Change in Acquisitions & Divestments (2015 - 2026)

Viking Therapeutics (VKTX) has 12 years of Change in Acquisitions & Divestments data on file, last reported at $126.6 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments fell 57.2% year-over-year to $126.6 million; the trailing twelve-month figure through Mar 2026 stood at $590.2 million (down 17.92% YoY), and the FY2025 full-year result was $759.4 million, up 35.61% from the prior year.
• Change in Acquisitions & Divestments advanced to $126.6 million in Q1 2026, from $116.1 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $295.9 million in Q1 2025 to a low of $32.3 million in Q1 2022.
• A 5-year average of $113.0 million and a median of $116.1 million in 2025 frame the typical range for Change in Acquisitions & Divestments.
• Across the five-year window, Change in Acquisitions & Divestments jumped 163.05% in 2024 and plunged 57.2% in 2026, its largest moves.
• Tracing VKTX's Change in Acquisitions & Divestments over 5 years: stood at $51.9 million in 2022, then soared by 156.94% to $133.3 million in 2023, then advanced by 7.71% to $143.5 million in 2024, then retreated by 19.12% to $116.1 million in 2025, then gained by 9.06% to $126.6 million in 2026.
• Business Quant data shows VKTX's Change in Acquisitions & Divestments at $126.6 million in Q1 2026, $116.1 million in Q4 2025, and $181.5 million in Q3 2025.